KIRCHMEYER, M.* , GAIGNEAUX, A.* , SERVAIS, F., Arslanow, A., Casper, M., Krawczyk, M., Lammert, F., & BEHRMANN, I. (2023). Altered profiles of circulating cytokines in chronic liver diseases (NAFLD/HCC): Impact of the PNPLA3I148M risk allele. Hepatology Communications. doi:10.1097/HC9.0000000000000306 Peer Reviewed verified by ORBi * These authors have contributed equally to this work. |
KIRCHMEYER, M., SERVAIS, F., GINOLHAC, A., Nazarov, P. V., MARGUE, C., PHILIPPIDOU, D., Nicot, N., BEHRMANN, I., HAAN, C., & KREIS, S. (2020). Systematic transcriptional profiling of responses to STAT1- and STAT3- activating cytokines in different cancer types. Journal of Molecular Biology. doi:10.1016/j.jmb.2020.09.011 Peer Reviewed verified by ORBi |
Walbrecq, G., MARGUE, C., BEHRMANN, I., & KREIS, S. (2020). Distinct Cargos of Small Extracellular Vesicles Derived from Hypoxic Cells and Their Effect on Cancer Cells. International Journal of Molecular Sciences. doi:10.3390/ijms21145071 Peer Reviewed verified by ORBi |
Walbrecq, G., Lecha, O., GAIGNEAUX, A., Fougeras, M. R., PHILIPPIDOU, D., MARGUE, C., TETSI NOMIGNI, M., Bernardin, F., DITTMAR, G., BEHRMANN, I., & KREIS, S. (2020). Hypoxia-Induced Adaptations of miRNomes and Proteomes in Melanoma Cells and Their Secreted Extracellular Vesicles. Cancers. doi:10.3390/cancers12030692 Peer Reviewed verified by ORBi |
Fernández-Tussy, P., Fernández-Ramos, D., Lopitz-Otsoa, F., Simón, J., Barbier-Torres, L., Gomez-Santos, B., Nuñez-Garcia, M., Azkargorta, M., Gutiérrez-de Juan, V., Serrano-Macia, M., Rodríguez-Agudo, R., Iruzubieta, P., Anguita, J., Castro, R. E., Champagne, D., Rincón, M., Elortza, F., Arslanow, A., Krawczyk, M., ... Martinez_Chantar, M. (2019). miR-873-5p targets mitochondrialGNMT-Complex II interface contributing tonon-alcoholic fatty liver disease. Molecular Metabolism. doi:10.1016/j.molmet.2019.08.008 Peer reviewed |
SERVAIS, F., KIRCHMEYER, M., HAMDORF, M., MINOUNGOU, W. N., Rose-John, S., KREIS, S., HAAN, C., & BEHRMANN, I. (2019). Modulation of the IL-6 signaling pathway in liver cells by miRNAs targeting gp130, JAK1 and/or STAT3. Molecular Therapy: Nucleic Acids, 16, 419-433. doi:10.1016/j.omtn.2019.03.007 Peer Reviewed verified by ORBi |
ROLVERING, C., ZIMMER, A. D., GINOLHAC, A., MARGUE, C., KIRCHMEYER, M., SERVAIS, F., Hermanns, H. M., Hergovits, S., Nazarov, P. V., Nicot, N., KREIS, S., HAAN, S., BEHRMANN, I., & HAAN, C. (2018). The PD-L1- and IL6-mediated dampening of the IL27/STAT1 anticancer responses are prevented by a-PD-L1 or a-IL6 antibodies. Journal of Leukocyte Biology, 104, 969-985. doi:10.1002/JLB.MA1217-495R Peer Reviewed verified by ORBi |
Kirchmeyer, M., SERVAIS, F., Hamdorf, M., Nazarov, P. V., GINOLHAC, A., HALDER, R., Vallar, L., Glanemann, M., Rubie, C., Lammert, F., KREIS, S., & BEHRMANN, I. (2018). Cytokine-mediated modulation of the hepatic miRNome: miR-146b-5p is an IL-6-inducible miRNA with multiple targets. Journal of Leukocyte Biology. doi:10.1002/JLB.MA1217-499RR Peer Reviewed verified by ORBi |
ROLVERING, C., Zimmer, A., KOZAR, I., Hermanns, LETELLIER, E., Vallar, L., Nazarov, P., Nicot, N., GINOLHAC, A., HAAN, S., BEHRMANN, I., & HAAN, C. (2017). Crosstalk between different family members: IL27 recapitulates IFNγ responses in HCC cells, but is inhibited by IL6-type cytokines. Biochimica et Biophysica Acta. Molecular Cell Research, 516-526. doi:10.1016/J.BBAMCR.2016.12.006 Peer Reviewed verified by ORBi |
Bongartz, H., Hessenkemper, W., Müller, C., Fensky, M., Fritsch, J., Mandel, K., BEHRMANN, I., HAAN, C., Fischer, T., Feller, S. M., & Schaper, F. (2017). The multi-site docking protein Gab1 is constitutively phosphorylated independent from its recruitment to the plasma membrane in Jak2-V617Fpositive cells and mediates proliferation of human erythroleukaemia cells. Cellular Signalling, 35, 37-47. doi:10.1016/j.cellsig.2017.03.021 Peer reviewed |
Casper, M., Krawczyk, M., BEHRMANN, I., Glanemann, M., & Lammert, F. (2016). Variant PNPLA3 increases the HCC risk: prospective study in patients treated at the Saarland University Medical Center. Zeitschrift für Gastroenterologie, 54, 585-586. doi:10.1055/s-0042-106308 Peer Reviewed verified by ORBi |
ZIMMER, A. D., WALBRECQ, G., KOZAR, I., BEHRMANN, I., & HAAN, C. (2016). Phosphorylation of the PDH complex precedes HIF-1-mediated effects and PDK1 upregulation during the first hours of hypoxic treatment in HCC cells. Hypoxia, 4, 135-145. doi:10.2147/HP.S99044 Peer reviewed |
BATTELLO, N., ZIMMER, A. D., Goebel, C., DONG, X., BEHRMANN, I., HAAN, C., HILLER, K., & Wegner, A. (2016). The role of HIF-1 in oncostatin M-dependent metabolic reprogramming of hepatic cells. Cancer and Metabolism, 4, 3. doi:10.1186/s40170-016-0141-0 Peer Reviewed verified by ORBi |
BEHRMANN, I., MARGUE, C., & KREIS, S. (2015). Circulating microRNAs as candidate biomarkers for the surveillance of melanoma patients. EBioMedicine. doi:10.1016/j.ebiom.2015.07.015 Peer Reviewed verified by ORBi |
MARGUE, C., REINSBACH, S., PHILIPPIDOU, D., BEAUME, N., Walters, C., SCHNEIDER, J., Nashan, D., BEHRMANN, I., & KREIS, S. (2015). Comparison of a healthy miRNome with melanoma patient miRNomes: are microRNAs suitable serum biomarkers for cancer? Oncotarget, 6 (14), 12110-27. doi:10.18632/oncotarget.3661 Peer Reviewed verified by ORBi |
SERVAIS, F., Kirchmeyer, M., HAMDORF, M., HAAN, C., Casper, M., Lammert, F., Nazarov, P., Vallar, L., KREIS, S., & BEHRMANN, I. (2015). ID: 194: Role of microRNAs in signal transduction pathways of the inflammatory cytokine Interleukin-6: Relevance for liver diseases. Cytokine, 76 (1), 99. doi:10.1016/j.cyto.2015.08.198 Peer reviewed |
MARGUE, C., PHILIPPIDOU, D., REINSBACH, S., SCHMITT, M., BEHRMANN, I., & KREIS, S. (05 September 2013). New Target Genes of MITF-Induced microRNA-211 Contribute to Melanoma Cell Invasion. PLoS ONE, 8 (9). doi:10.1371/journal.pone.0073473 Peer Reviewed verified by ORBi |
Wolf, A., Eulenfeld, R., Gäbler, K., ROLVERING, C., HAAN, S., BEHRMANN, I., Denecke, B., HAAN, C., & Schaper, F. (2013). JAK2-V617F-induced MAPK activity is regulated by PI3K and acts synergistically with PI3K on the proliferation of JAK2-V617F-positive cells. JAK-STAT, 2 (3), 24574. doi:10.4161/jkst.24574 Peer reviewed |
Gäbler, K., BEHRMANN, I., & HAAN, C. (2013). JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms. JAK-STAT, 2 (3), 25025. doi:10.4161/jkst25025 Peer reviewed |
Gäbler, K., ROLVERING, C., KACZOR, J., Eulenfeld, R., Méndez, S. A., Berchem, G., Palissot, V., BEHRMANN, I., & HAAN, C. (2013). Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F. Journal of Cellular and Molecular Medicine, 17 (2), 265-276. doi:10.1111/jcmm.12005 Peer reviewed |
Schmitt, M. J., PHILIPPIDOU, D., REINSBACH, S., MARGUE, C., WIENECKE-BALDACCHINO, A., Nashan, D., BEHRMANN, I., & KREIS, S. (2012). Interferon-γ-induced activation of Signal Transducer and Activator of Transcription 1 (STAT1) up-regulates the tumor suppressing microRNA-29 family in melanoma cells. Cell Communication and Signaling, 10. doi:10.1186/1478-811X-10-41 Peer Reviewed verified by ORBi |
REINSBACH, S., Nazarov, P. V., PHILIPPIDOU, D., Schmitt, M., WIENECKE, A., Muller, A., Vallar, L., BEHRMANN, I., & KREIS, S. (2012). Dynamic regulation of microRNA expression following interferonγ- induced gene transcription. RNA Biology, 9 (7), 987-989. doi:10.4161/rna.20494 Peer Reviewed verified by ORBi |
Schmitt, M., MARGUE, C., BEHRMANN, I., & KREIS, S. (2012). MiRNA-29: A microRNA family with tumor-suppressing and immune-modulating properties. Current Molecular Medicine, 13 (4), 572-585. doi:10.2174/1566524011313040009 Peer Reviewed verified by ORBi |
HAAN, C., ROLVERING, C., Raulf, F., Kapp, M., Drückes, P., Thoma, G., BEHRMANN, I., & Zerwes, H.-G. (2011). Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors. Chemistry and Biology, 18 (3), 314-323. doi:10.1016/j.chembiol.2011.01.012 Peer reviewed |
PHILIPPIDOU, D., SCHMITT, M., Moser, D., MARGUE, C., Nazarov, P. V., Muller, A., Vallar, L., Nashan, D., BEHRMANN, I., & KREIS, S. (2010). Signatures of MicroRNAs and selected MicroRNA target genes in human melanoma. Cancer Research, 70 (10), 4163-4173. doi:10.1158/0008-5472.CAN-09-4512 Peer Reviewed verified by ORBi |
Radtke, S., Wüller, S., Yang, X.-P., Lippok, B. E., Mütze, B., Mais, C., Schmitz-Van De Leur, H., Bode, J. G., Gaestel, M., Heinrich, P. C., BEHRMANN, I., Schaper, F. A., & Hermanns, H. M. (2010). Cross-regulation of cytokine signalling: Pro-inflammatory cytokines restrict IL-6 signalling through receptor internalisation and degradation. Journal of Cell Science, 123 (6), 947-959. doi:10.1242/jcs.065326 Peer Reviewed verified by ORBi |
Entschladen, F., Altschmied, J., Baumgrass, R., BEHRMANN, I., Giehl, K., Hermanns, H., Huber, O., Kieser, A., Klotz, L.-O., Kubatzky, K. F., Hass, R., Janssen, O., & Friedrich, K. (2010). Signal transduction, receptors, mediators and genes: Younger than ever - The 13th meeting of the Signal Transduction Society focused on aging and immunology. Cell Communication and Signaling, 8. doi:10.1186/1478-811X-8-2 Peer Reviewed verified by ORBi |
VOLLMER, S., HAAN, C., & BEHRMANN, I. (2010). Oncostatin M up-regulates the ER chaperone Grp78/BiP in liver cells. Biochemical Pharmacology, 80 (12), 2066-2073. doi:10.1016/j.bcp.2010.07.015 Peer reviewed |
HAAN, C., BEHRMANN, I., & HAAN, S. (2010). Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases. Journal of Cellular and Molecular Medicine, 14 (3), 504-27. doi:10.1111/j.1582-4934.2010.01018.x Peer reviewed |
Friedrich, K., & BEHRMANN, I. (2009). Zelluläre Signalprozesse. In Biochemie und Molekularbiologie des Menschen (pp. 631-669). United States - Delaware: Elsevier. Peer reviewed |
HAAN, S., Wuller, S., KACZOR, J., ROLVERING, C., Nocker, T., BEHRMANN, I., & HAAN, C. (2009). SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling. Oncogene, 28 (34), 3069-80. doi:10.1038/onc.2009.155 Peer Reviewed verified by ORBi |
HAAN, C., Kroy, D. C., Wüller, S., Sommer, U., Nöcker, T., ROLVERING, C., BEHRMANN, I., Heinrich, P. C., & HAAN, S. (2009). An unusual insertion in Jak2 is crucial for kinase activity and differentially affects cytokine responses. Journal of Immunology, 182 (5), 2969-2977. doi:10.4049/jimmunol.0800572 Peer Reviewed verified by ORBi |
VOLLMER, S., Kappler, V., KACZOR, J., Flügel, D., ROLVERING, C., Kato, N., Kietzmann, T., BEHRMANN, I., & HAAN, C. (2009). Hypoxia-inducible factor 1alpha is up-regulated by oncostatin M and participates in oncostatin M signaling. Hepatology, 2009 (3). doi:10.1002/hep.22928 Peer Reviewed verified by ORBi |
KREIS, S., PHILIPPIDOU, D., MARGUE, C., & BEHRMANN, I. (10 May 2008). IL-24: a classic cytokine and/or a potential cure for cancer? Journal of Cellular and Molecular Medicine, 12 (6A), 2505-2510. doi:10.1111/j.1582-4934.2008.00372.x Peer reviewed |
KREIS, S., Munz, G. A., HAAN, S., Heinrich, P. C., & BEHRMANN, I. (2008). Cell density dependent increase of constitutive signal transducers and activators of transcription 3 activity in melanoma cells is mediated by Janus kinases. Molecular Cancer Research, 5 (12), 1331-41. doi:10.1158/1541-7786.MCR-07-0317 Peer Reviewed verified by ORBi |
HAAN, S., MARGUE, C., Engrand, A., ROLVERING, C., Schmitz-Van de Leur, H., Heinrich, P. C., BEHRMANN, I., & HAAN, C. (2008). Dual role of the Jak1 FERM and kinase domains in cytokine receptor binding and in stimulation-dependent Jak activation. Journal of Immunology, 180 (2), 998-1007. doi:10.4049/jimmunol.180.2.998 Peer Reviewed verified by ORBi |
KREIS, S., PHILIPPIDOU, D., MARGUE, C., ROLVERING, C., HAAN, C., Dumoutier, L., Renauld, J.-C., & BEHRMANN, I. (2007). Recombinant interleukin-24 lacks apoptosis-inducing properties in melanoma cells. PLoS ONE, 2 (12), 1300. doi:10.1371/journal.pone.0001300 Peer Reviewed verified by ORBi |
HAAN, C., & BEHRMANN, I. (2007). A cost effective non-commercial ECL-solution for Western blot detections yielding strong signals and low background. Journal of Immunological Methods, 318 (1-2), 11-9. doi:10.1016/j.jim.2006.07.027 Peer reviewed |
Komyod, W., Böhm, M., Metze, D., Heinrich, P. C., & BEHRMANN, I. (2007). Constitutive suppressor of cytokine signaling 3 expression confers a growth advantage to a human melanoma cell line. Molecular Cancer Research, 5 (3), 271-81. doi:10.1158/1541-7786.MCR-06-0274 Peer Reviewed verified by ORBi |
Soond, S. M., Carroll, C., Townsend, P. A., Sayan, E., Melino, G., BEHRMANN, I., Knight, R. A., Latchman, D. S., & Stephanou, A. (2007). STAT1 regulates p73-mediated Bax gene expression. FEBS Letters, 581 (6), 1217-26. doi:10.1016/j.febslet.2007.02.049 Peer Reviewed verified by ORBi |
HAAN, C., KREIS, S., MARGUE, C., & BEHRMANN, I. (November 2006). Jaks and cytokine receptors - an intimate relationship. Biochemical Pharmacology, 72 (11), 1538-46. doi:10.1016/j.bcp.2006.04.013 Peer Reviewed verified by ORBi |
van Roeyen, C. R., Ostendorf, T., Denecke, B., Bokemeyer, D., BEHRMANN, I., Strutz, F., Lichenstein, H. S., LaRochelle, W. J., Pena, C. E., Chaudhuri, A., & Floege, J. (2006). Biological responses to PDGF-BB versus PDGF-DD in human mesangial cells. Kidney International, 69 (8), 1393-402. doi:10.1038/sj.ki.5000332 Peer Reviewed verified by ORBi |
Radtke, S., Jörissen, A., de Leur, H. S., Heinrich, P. C., & BEHRMANN, I. (2006). Three dileucine-like motifs within the interbox1/2 region of the human oncostatin M receptor prevent efficient surface expression in the absence of an associated Janus kinase. Journal of Biological Chemistry, 281 (7), 4024-34. doi:10.1074/jbc.M511779200 Peer Reviewed verified by ORBi |
Hellerbrand, C., Mühlbauer, M., Wallner, S., Schuierer, M., BEHRMANN, I., Bataille, F., Weiss, T., Schölmerich, J., & Bosserhoff, A. K. (2005). Promoter-hypermethylation is causing functional relevant downregulation of methylthioadenosine phosphorylase (MTAP) expression in hepatocellular carcinoma. Carcinogenesis, 27 (1), 64-72. doi:10.1093/carcin/bgi201 Peer Reviewed verified by ORBi |
Wellbrock, C., Weisser, C., Hassel, J. C., Fischer, P., Becker, J., Vetter, C. S., BEHRMANN, I., Kortylewski, M., Heinrich, P. C., & Schartl, M. (2005). STAT5 contributes to interferon resistance of melanoma cells. Current Biology, 15 (18), 1629-39. doi:10.1016/j.cub.2005.08.036 Peer reviewed |
Komyod, W., Bauer, U. M., Heinrich, P. C., HAAN, S., & BEHRMANN, I. (2005). Are STATS arginine-methylated? Journal of Biological Chemistry, 280 (23), 21700-5. doi:10.1074/jbc.C400606200 Peer Reviewed verified by ORBi |
Radtke, S.* , HAAN, S.* , Jörissen, A.* , Hermanns, H. M., Diefenbach, S., Smyczek, T., Schmitz-Vandeleur, H., Heinrich, P. C., BEHRMANN, I., & HAAN, C. (2005). The Jak1 SH2 domain does not fulfill a classical SH2 function in Jak/STAT signaling but plays a structural role for receptor interaction and up-regulation of receptor surface expression. Journal of Biological Chemistry, 280 (27), 25760-8. doi:10.1074/jbc.M500822200 Peer Reviewed verified by ORBi * These authors have contributed equally to this work. |
HAAN, S., Keller, J. F., BEHRMANN, I., Heinrich, P. C., & HAAN, C. (2005). Multiple reasons for an inefficient STAT1 response upon IL-6-type cytokine stimulation. Cellular Signalling, 17 (12), 1542-50. doi:10.1016/j.cellsig.2005.03.010 Peer Reviewed verified by ORBi |
BEHRMANN, I., Smyczek, T., Heinrich, P. C., Schmitz-Van de Leur, H., Komyod, W., Giese, B., Muller-Newen, G., HAAN, S., & HAAN, C. (2004). Janus kinase (Jak) subcellular localization revisited: the exclusive membrane localization of endogenous Janus kinase 1 by cytokine receptor interaction uncovers the Jak.receptor complex to be equivalent to a receptor tyrosine kinase. Journal of Biological Chemistry, 279 (34), 35486-93. doi:10.1074/jbc.M404202200 Peer Reviewed verified by ORBi |
Kortylewski, M., Komyod, W., Kauffmann, M. E., Bosserhoff, A. K., Heinrich, P. C., & BEHRMANN, I. (2004). Interferon-gamma-mediated growth regulation of melanoma cells: involvement of STAT1-dependent and STAT1-independent signals. Journal of Investigative Dermatology, 122 (2), 414-22. doi:10.1046/j.0022-202X.2004.22237.x Peer Reviewed verified by ORBi |
Fischer, P., Lehmann, U., Sobota, R. M., Schmitz, J., Niemand, C., Linnemann, S., HAAN, S., BEHRMANN, I., Yoshimura, A., Johnston, J. A., Müller-Newen, G., Heinrich, P. C., & Schaper, F. (2004). The role of the inhibitors of interleukin-6 signal transduction SHP2 and SOCS3 for desensitization of interleukin-6 signalling. Biochemical Journal, 378 (Pt 2), 449-60. doi:10.1042/BJ20030893 Peer Reviewed verified by ORBi |
Giese, B., Au-Yeung, C. K., Herrmann, A., Diefenbach, S., HAAN, C., Küster, A., Wortmann, S. B., Roderburg, C., Heinrich, P. C., BEHRMANN, I., & Müller-Newen, G. (2003). Long term association of the cytokine receptor gp130 and the Janus kinase Jak1 revealed by FRAP analysis. Journal of Biological Chemistry, 278 (40), 39205-13. doi:10.1074/jbc.M303347200 Peer Reviewed verified by ORBi |
Kortylewski, M., Feld, F., Krüger, K. D., Bahrenberg, G., Roth, R. A., Joost, H. G., Heinrich, P. C., BEHRMANN, I., & Barthel, A. (2003). Akt modulates STAT3-mediated gene expression through a FKHR (FOXO1a)-dependent mechanism. Journal of Biological Chemistry, 278 (7), 5242-9. doi:10.1074/jbc.M205403200 Peer Reviewed verified by ORBi |
BEHRMANN, I., Wallner, S., Komyod, W., Heinrich, P. C., Schuierer, M., Buettner, R., & Bosserhoff, A. K. (2003). Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma. American Journal of Pathology, 163 (2), 683-90. doi:10.1016/S0002-9440(10)63695-4 Peer Reviewed verified by ORBi |
Heinrich, P. C.* , BEHRMANN, I.* , HAAN, S.* , Hermanns, H. M.* , Müller-Newen, G.* , & Schaper, F.*. (2003). Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochemical Journal, 374 (Pt 1), 1-20. doi:10.1042/BJ20030407 Peer Reviewed verified by ORBi * These authors have contributed equally to this work. |
Lehmann, U., Schmitz, J., Weissenbach, M., Sobota, R. M., Hortner, M., Friederichs, K., BEHRMANN, I., Tsiaris, W., Sasaki, A., Schneider-Mergener, J., Yoshimura, A., Neel, B. G., Heinrich, P. C., & Schaper, F. (2002). SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130. Journal of Biological Chemistry, 278 (1), 661-71. doi:10.1074/jbc.M210552200 Peer Reviewed verified by ORBi |
Bahrenberg, G., BEHRMANN, I., Barthel, A., Hekerman, P., Heinrich, P. C., Joost, H. G., & BECKER, W. (2002). Identification of the critical sequence elements in the cytoplasmic domain of leptin receptor isoforms required for Janus kinase/signal transducer and activator of transcription activation by receptor heterodimers. Molecular Endocrinology, 16 (4), 859-72. doi:10.1210/mend.16.4.0800 Peer Reviewed verified by ORBi |
Roeb, E., Schleinkofer, K., Kernebeck, T., Pötsch, S., Jansen, B., BEHRMANN, I., Matern, S., & Grötzinger, J. (2002). The matrix metalloproteinase 9 (mmp-9) hemopexin domain is a novel gelatin binding domain and acts as an antagonist. Journal of Biological Chemistry, 277 (52), 50326-32. doi:10.1074/jbc.M207446200 Peer Reviewed verified by ORBi |
Greiser, J. S., Stross, C., Heinrich, P. C., BEHRMANN, I., & Hermanns, H. M. (2002). Orientational constraints of the gp130 intracellular juxtamembrane domain for signaling. Journal of Biological Chemistry, 277 (30), 26959-65. doi:10.1074/jbc.M204113200 Peer Reviewed verified by ORBi |
Radtke, S., Hermanns, H. M., HAAN, C., Schmitz-Van De Leur, H., Gascan, H., Heinrich, P. C., & BEHRMANN, I. (2002). Novel role of Janus kinase 1 in the regulation of oncostatin M receptor surface expression. Journal of Biological Chemistry, 277 (13), 11297-305. doi:10.1074/jbc.M100822200 Peer Reviewed verified by ORBi |
HAAN, C., Isharc, H., Hermanns, H. M., Schmitz-Van De Leur, H., Kerr, I. M., Heinrich, P. C., Grötzinger, J., & BEHRMANN, I. (2001). Mapping of a region within the N terminus of Jak1 involved in cytokine receptor interaction. Journal of Biological Chemistry, 276 (40), 37451-8. doi:10.1074/jbc.M106135200 Peer Reviewed verified by ORBi |
HAAN, C., Hermanns, H. M., Heinrich, P. C., & BEHRMANN, I. (2001). A single amino acid substitution (Trp(666)-->Ala) in the interbox1/2 region of the interleukin-6 signal transducer gp130 abrogates binding of JAK1, and dominantly impairs signal transduction. Biochemical Journal, 349 (Pt 1), 261-6. doi:10.1042/0264-6021:3490261 Peer Reviewed verified by ORBi |
Böhm, M., Schulte, U., Funk, J. O., Raghunath, M., BEHRMANN, I., Kortylewski, M., Heinrich, P. C., Kues, T., Luger, T. A., & Schwarz, T. (2001). Interleukin-6-resistant melanoma cells exhibit reduced activation of STAT3 and lack of inhibition of cyclin E-associated kinase activity. Journal of Investigative Dermatology, 117 (1), 132-40. doi:10.1046/j.0022-202x.2001.01372.x Peer Reviewed verified by ORBi |
HAAN, C., Heinrich, P. C., & BEHRMANN, I. (2001). Structural requirements of the interleukin-6 signal transducer gp130 for its interaction with Janus kinase 1: the receptor is crucial for kinase activation. Biochemical Journal, 361 (Pt 1), 105-11. doi:10.1042/0264-6021:3610105 Peer Reviewed verified by ORBi |
Zabeau, L., Van der Heyden, J., Broekaert, D., Verhee, A., Vandekerckhove, J., Wu, S. J., Chaiken, I., Heinrich, P., BEHRMANN, I., & Tavernier, J. (2001). Neutralizing monoclonal antibodies can potentiate IL-5 signaling. European Journal of Immunology, 31 (4), 1087-97. doi:10.1002/1521-4141(200104)31:4<1087::AID-IMMU1087>3.0.CO;2-Q Peer reviewed |
Hermanns, H. M., Radtke, S., Schaper, F., Heinrich, P. C., & BEHRMANN, I. (2001). Non-redundant signal transduction of interleukin-6-type cytokines. The adapter protein Shc is specifically recruited to rhe oncostatin M receptor. Journal of Biological Chemistry, 275 (52), 40742-8. doi:10.1074/jbc.M005408200 Peer Reviewed verified by ORBi |
Kube, D., Holtick, U., Vockerodt, M., Ahmadi, T., Haier, B., BEHRMANN, I., Heinrich, P. C., Diehl, V., & Tesch, H. (2001). STAT3 is constitutively activated in Hodgkin cell lines. Blood, 98 (3), 762-70. doi:10.1182/blood.V98.3.762 Peer Reviewed verified by ORBi |
Kortylewski, M., Heinrich, P. C., Kauffmann, M. E., Böhm, M., MacKiewicz, A., & BEHRMANN, I. (2001). Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells. Biochemical Journal, 357 (Pt 1), 297-303. doi:10.1042/0264-6021:3570297 Peer Reviewed verified by ORBi |
Kortylewski, M., Heinrich, P. C., Mackiewicz, A., & BEHRMANN, I. (2001). Cytokine-mediated growth inhibition of human melanoma cells. Advances in Experimental Medicine and Biology, 495, 169-72. doi:10.1007/978-1-4615-0685-0_22 Peer reviewed |
Strobl, B., Arulampalam, V., Isharc, H., Newman, S. J., Schlaak, J. F., Watling, D., Costa-Pereira, A. P., Schaper, F., BEHRMANN, I., Sheehan, K. C., Schreiber, R. D., Horn, F., Heinrich, P. C., & Kerr, I. M. (2001). A completely foreign receptor can mediate an interferon-gamma-like response. EMBO Journal, 20 (19), 5431-42. doi:10.1093/emboj/20.19.5431 Peer Reviewed verified by ORBi |
Hilkens, C. M., Isharc, H., Lillemeier, B. F., Strobl, B., Bates, P. A., BEHRMANN, I., & Kerr, I. M. (2001). A region encompassing the FERM domain of Jak1 is necessary for binding to the cytokine receptor gp130. FEBS Letters, 505 (1), 87-91. doi:10.1016/S0014-5793(01)02783-1 Peer Reviewed verified by ORBi |
HAAN, S., Kortylewski, M., BEHRMANN, I., Müller-Esterl, W., Heinrich, P. C., & Schaper, F. (2000). Cytoplasmic STAT proteins associate prior to activation. Biochemical Journal, 345 Pt 3, 417-21. doi:10.1042/0264-6021:3450417 Peer Reviewed verified by ORBi |
BEHRMANN, I., Hermanns, H. M., HAAN, C., Kortylewski, M., Radtke, S., Greiser, J. S., & Heinrich, P. C. (2000). Signalling of interleukin-6 type cytokines via gp130, leukemia inhibitory factor (LIF) receptor and oncostatin M receptor. European Cytokine Network, 11 (3), 491-2. Peer Reviewed verified by ORBi |
Roeb, E., BEHRMANN, I., Grötzinger, J., Breuer, B., & Matern, S. (2000). An MMP-9 mutant without gelatinolytic activity as a novel TIMP-1-antagonist. FASEB Journal, 14 (12), 1671-3. doi:10.1096/fj.99-0947fje Peer Reviewed verified by ORBi |
Hermanns, H. M., Radtke, S., HAAN, C., Schmitz-Van de Leur, H., Tavernier, J., Heinrich, P. C., & BEHRMANN, I. (2000). Contributions of leukemia inhibitory factor receptor and oncostatin M receptor to signal transduction in heterodimeric complexes with glycoprotein 130. Journal of Immunology, 163 (12), 6651-8. Peer Reviewed verified by ORBi |
Anhuf, D., Weissenbach, M., Schmitz, J., Sobota, R., Hermanns, H. M., Radtke, S., Linnemann, S., BEHRMANN, I., Heinrich, P. C., & Schaper, F. (2000). Signal transduction of IL-6, leukemia-inhibitory factor, and oncostatin M: structural receptor requirements for signal attenuation. Journal of Immunology, 165 (5), 2535-43. doi:10.4049/jimmunol.165.5.2535 Peer Reviewed verified by ORBi |
Terstegen, L., Maassen, B. G., Radtke, S., BEHRMANN, I., Schaper, F., Heinrich, P. C., Graeve, L., & Gatsios, P. (2000). Differential inhibition of IL-6-type cytokine-induced STAT activation by PMA. FEBS Letters, 478 (1-2), 100-4. doi:10.1016/S0014-5793(00)01826-3 Peer Reviewed verified by ORBi |
Thiel, S., Sommer, U., Kortylewski, M., HAAN, C., BEHRMANN, I., Heinrich, P. C., & Graeve, L. (2000). Termination of IL-6-induced STAT activation is independent of receptor internalization but requires de novo protein synthesis. FEBS Letters, 470 (1), 15-9. doi:10.1016/S0014-5793(00)01276-X Peer Reviewed verified by ORBi |
Kortylewski, M., Heinrich, P. C., Mackiewicz, A., Schniertshauer, U., Klingmüller, U., Nakajima, K., Hirano, T., Horn, F., & BEHRMANN, I. (1999). Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1. Oncogene, 18 (25), 3742-53. doi:10.1038/sj.onc.1202708 Peer Reviewed verified by ORBi |
Thiel, S., BEHRMANN, I., Timmermann, A., Dahmen, H., Müller-Newen, G., Schaper, F., Tavernier, J., Pitard, V., Heinrich, P. C., & Graeve, L. (1999). Identification of a Leu-lle internalization motif within the cytoplasmic domain of the leukaemia inhibitory factor receptor. Biochemical Journal, 339 (Pt 1), 15-9. doi:10.1042/0264-6021:3390015 Peer Reviewed verified by ORBi |
Heinrich, P. C., BEHRMANN, I., Müller-Newen, G., Schaper, F., & Graeve, L. (1998). Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochemical Journal, 334 (Pt 2), 297-314. doi:10.1042/bj3340297 Peer Reviewed verified by ORBi |
Thiel, S., BEHRMANN, I., Dittrich, E., Muys, L., Tavernier, J., Wijdenes, J., Heinrich, P. C., & Graeve, L. (1998). Internalization of the interleukin 6 signal transducer gp130 does not require activation of the Jak/STAT pathway. Biochemical Journal, 330 (Pt 1), 47-54. doi:10.1042/bj3300047 Peer Reviewed verified by ORBi |
BEHRMANN, I., Janzen, C., Gerhartz, C., Schmitz-Van de Leur, H., Hermanns, H., Heesel, B., Graeve, L., Horn, F., Tavernier, J., & Heinrich, P. C. (1997). A single STAT recruitment module in a chimeric cytokine receptor complex is sufficient for STAT activation. Journal of Biological Chemistry, 272 (8), 5269-74. doi:10.1074/jbc.272.8.5269 Peer Reviewed verified by ORBi |
Kischkel, F. C., Hellbardt, S., BEHRMANN, I., Germer, M., Pawlita, M., Krammer, P. H., & Peter, M. E. (1996). Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO Journal, 14 (22), 5579-88. doi:10.1002/j.1460-2075.1995.tb00245.x Peer Reviewed verified by ORBi |
BEHRMANN, I., Walczak, H., & Krammer, P. H. (1995). Structure of the human APO-1 gene. European Journal of Immunology, 24 (12), 3057-62. doi:10.1002/eji.1830241221 Peer reviewed |
Krammer, P. H., Dhein, J., Walczak, H., BEHRMANN, I., Mariani, S., Matiba, B., Fath, M., Daniel, P. T., Knipping, E., & Westendorp, M. O. (1995). The role of APO-1-mediated apoptosis in the immune system. Immunological Reviews, 142, 175-91. doi:10.1111/j.1600-065X.1994.tb00889.x Peer Reviewed verified by ORBi |
Dhein, J., BEHRMANN, I., Daniel, P. T., Debatin, K. M., Klas, C., Möller, P., Oehm, A., Trauth, B. C., Walczak, H., & Krammer, P. H. (1995). APO-I-mediated apoptosis in normal and malignant lymphocytes. Biochemical Society Transactions, 22 (3), 598-600. doi:10.1042/bst0220598 Peer reviewed |
Krammer, P. H., BEHRMANN, I., Daniel, P. T., Dhein, J., & Debatin, K. M. (1994). Regulation of apoptosis in the immune system. Current Opinion in Immunology, 6 (2), 279-89. doi:10.1016/0952-7915(94)90102-3 Peer reviewed |
Oehm, A., BEHRMANN, I., Falk, W., Pawlita, M., Maier, G., Klas, C., Li-Weber, M., Richards, S., Dhein, J., & Trauth, B. C. (1992). Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. Journal of Biological Chemistry, 267 (15), 10709-15. Peer Reviewed verified by ORBi |
BEHRMANN, I., Hillemann, D., Pühler, A., Strauch, E., & Wohlleben, W. (1990). Overexpression of a Streptomyces viridochromogenes gene (glnII) encoding a glutamine synthetase similar to those of eucaryotes confers resistance against the antibiotic phosphinothricyl-alanyl-alanine. Journal of Bacteriology, 172 (9), 5326-34. doi:10.1128/jb.172.9.5326-5334.1990 Peer Reviewed verified by ORBi |